Predictors of low and very low bone mineral density in long-term childhood acute lymphoblastic leukemia survivors: Toward personalized risk prediction.
bone health in children
bone mineral density
cancer treatment toxicity
childhood acute lymphoblastic leukemia
childhood cancer survivor
late cancer effects
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
12 May 2024
12 May 2024
Historique:
revised:
15
03
2024
received:
28
11
2023
accepted:
16
04
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
Cohorts of childhood acute lymphoblastic leukemia (cALL) survivors reaching adulthood are increasing. Approximately 30% of survivors meet criteria for low bone mineral density (BMD) 10 years after diagnosis. We investigated risk factors for low BMD in long-term cALL survivors. We recruited 245 cALL survivors from the PETALE (Prévenir les effets tardifs des traitements de la leucémie aiguë lymphoblastique chez l'enfant) cohort, who were treated with the Dana Farber Cancer Institute protocols, did not experience disease relapse or hematopoietic stem cell transplants, and presented with more than 5 years of event-free survival. Median time since diagnosis was 15.1 years. Prevalence of low DXA-derived BMD (Z-score ≤-1) ranged between 21.9% and 25.3%, depending on site (lumbar spine (LS-BMD), femoral neck (FN-BMD), and total body (TB-BMD), and between 3.7% and 5.8% for very low BMD (Z-score ≤-2). Males had a higher prevalence of low BMD than females for all three outcomes (26%-32% vs. 18%-21%), and male sex acted as a significant risk factor for low BMD in all models. Treatment-related factors such as cumulative glucocorticoid (GC) doses and cranial radiation therapy (CRT) were associated with lower BMDs in the full cohort and in females at the FN-BMD site. Low and very low BMD is more prevalent in male cALL survivors. Male sex, high cumulative GC doses, CRT, risk group, and low body mass index (BMI) were identified as risk factors for low BMD. A longer follow-up of BMD through time in these survivors is needed to establish if low BMD will translate into a higher risk for fragility fractures through adulthood.
Sections du résumé
BACKGROUND
BACKGROUND
Cohorts of childhood acute lymphoblastic leukemia (cALL) survivors reaching adulthood are increasing. Approximately 30% of survivors meet criteria for low bone mineral density (BMD) 10 years after diagnosis. We investigated risk factors for low BMD in long-term cALL survivors.
METHODS
METHODS
We recruited 245 cALL survivors from the PETALE (Prévenir les effets tardifs des traitements de la leucémie aiguë lymphoblastique chez l'enfant) cohort, who were treated with the Dana Farber Cancer Institute protocols, did not experience disease relapse or hematopoietic stem cell transplants, and presented with more than 5 years of event-free survival. Median time since diagnosis was 15.1 years.
RESULTS
RESULTS
Prevalence of low DXA-derived BMD (Z-score ≤-1) ranged between 21.9% and 25.3%, depending on site (lumbar spine (LS-BMD), femoral neck (FN-BMD), and total body (TB-BMD), and between 3.7% and 5.8% for very low BMD (Z-score ≤-2). Males had a higher prevalence of low BMD than females for all three outcomes (26%-32% vs. 18%-21%), and male sex acted as a significant risk factor for low BMD in all models. Treatment-related factors such as cumulative glucocorticoid (GC) doses and cranial radiation therapy (CRT) were associated with lower BMDs in the full cohort and in females at the FN-BMD site.
CONCLUSION
CONCLUSIONS
Low and very low BMD is more prevalent in male cALL survivors. Male sex, high cumulative GC doses, CRT, risk group, and low body mass index (BMI) were identified as risk factors for low BMD. A longer follow-up of BMD through time in these survivors is needed to establish if low BMD will translate into a higher risk for fragility fractures through adulthood.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31047Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2024 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian cancer statistics. Government of Canada; 2016.
Cancer facts and figures. American Cancer Society; 2014. Accessed on November 15th, 2022. http://www.cancer.gov/types/leukemia/hp/child‐all‐treatment‐pdq#cit/section_1.5
Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371‐2381.
Casillas J, Sakamoto KM. Topics in pediatric leukemia–acute lymphoblastic leukemia and late effects in long‐term survivors. MedGenMed. 2005;7(1):22.
Chemaitilly W, Cohen LE, Mostoufi‐Moab S, et al. Endocrine late effects in childhood cancer survivors. J Clin Oncol. 2018;36(21):2153‐2159.
Brignardello E, Felicetti F, Castiglione A, et al. Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult‐focused follow‐up clinics. Eur J Endocrinol. 2013;168(3):465‐472.
Siegel DA, Claridy M, Mertens A, et al. Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors. Pediatr Blood Cancer. 2017;64(9):e26488.
Polgreen LE, Petryk A, Dietz AC, et al. Modifiable risk factors associated with bone deficits in childhood cancer survivors. BMC Pediatr. 2012;12:40.
Thomas IH, Donohue JE, Ness KK, Dengel DR, Baker KS, Gurney JG. Bone mineral density in young adult survivors of acute lymphoblastic leukemia. Cancer. 2008;113(11):3248‐3356.
Ward LM, Ma J, Lang B, et al. Bone morbidity and recovery in children with acute lymphoblastic leukemia: results of a six‐year prospective cohort study. J Bone Miner Res. 2018;33(8):1435‐1443.
Gurney JG, Kaste SC, Liu W, et al. Bone mineral density among long‐term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer. 2014;61(7):1270‐1276.
Tillmann V, Darlington ASE, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. J Bone Miner Res. 2002;17(6):1073‐1080.
Kaste Sc, Jones‐Wallace D, Rose Sr, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia. 2001;15(5):728‐734.
Joyce ED, Nolan VG, Ness KK, et al. Association of muscle strength and bone mineral density in adult survivors of childhood acute lymphoblastic leukemia. Arch Phys Med Rehabil. 2011;92(6):873‐879.
Wilson CL, Chemaitilly W, Jones KE, et al. Modifiable factors associated with aging phenotypes among adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2016;34(21):2509‐2515.
Fiscaletti M, Samoilenko M, Dubois J, et al. Predictors of vertebral deformity in long‐term survivors of childhood acute lymphoblastic leukemia: the PETALE study. J Clin Endocrinol Metab. 2021;106(2):512‐525.
Van Atteveld JE, Mulder RL, Van Den Heuvel‐Eibrink MM, et al. Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence‐based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes Endocrinol. 2021;9(9):622‐637.
Landier W, Armenian SH, Lee J, et al. Yield of screening for long‐term complications using the children's oncology group long‐term follow‐up guidelines. J Clin Oncol. 2012;30(35):4401‐4408.
Van Atteveld JE, Pluijm SMF, Ness KK, et al. Prediction of low and very low bone mineral density among adult survivors of childhood cancer. J Clin Oncol. 2019;37(25):2217‐2225.
Marcoux S, Drouin S, Laverdière C, et al. The PETALE study: late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors. Pediatr Blood Cancer. 2017;64(6):e26361.
Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(9):1079‐1109.
Obesity and overweight. Who.int; last updated 2024.
De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta‐analysis. Osteoporos Int. 2005;16(11):1330‐1338.
Caru M, Petrykey K, Drouin S, et al. Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors. BMC Cancer. 2019;19(1):443.
Paridon SM, Alpert BS, Boas SR, et al. Clinical stress testing in the pediatric age group: a statement from the American Heart Association Council on Cardiovascular Disease in the Young, Committee on Atherosclerosis, Hypertension, and Obesity in Youth. Circulation. 2006;113(15):1905‐1920.
Lemay V, Caru M, Samoilenko M, et al. Prevention of long‐term adverse health outcomes with cardiorespiratory fitness and physical activity in childhood acute lymphoblastic leukemia survivors. J Pediatr Hematol Oncol. 2019;41(7):e450‐e458.
Mäkitie O, Heikkinen R, Toiviainen‐Salo S, Henriksson M, Puukko‐Viertomies L‐R, Jahnukainen K. Long‐term skeletal consequences of childhood acute lymphoblastic leukemia in adult males: a cohort study. Eur J Endocrinol. 2013;168(2):281‐288.
Den Hoed MAH, Klap BC, Te Winkel ML, et al. Bone mineral density after childhood cancer in 346 long‐term adult survivors of childhood cancer. Osteoporos Int. 2015;26(2):521‐529.
Hayek S, Gibson TM, Leisenring WM, et al. Prevalence and predictors of frailty in childhood cancer survivors and siblings: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2020;38(3):232‐247.
Ness KK, Armstrong GT, Kundu M, Wilson CL, Tchkonia T, Kirkland JL. Frailty in childhood cancer survivors. Cancer. 2015;121(10):1540‐1547.
Artaza‐Artabe I, Sáez‐López P, Sánchez‐Hernández N, Fernández‐Gutierrez N, Malafarina V. The relationship between nutrition and frailty: effects of protein intake, nutritional supplementation, vitamin D and exercise on muscle metabolism in the elderly. A systematic review. Maturitas. 2016;93:89‐99.
Bélanger V, Delorme J, Napartuk M, et al. Early nutritional intervention to promote healthy eating habits in pediatric oncology: a feasibility study. Nutrients. 2022;14(5):1024.
Karol SE, Yang W, Van Driest SL, et al. Genetics of glucocorticoid‐associated osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2015;126(15):1770‐1776.
Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340‐2347.
Te Winkel ML, Pieters R, Wind E‐JD, Bessems JHJM, Van Den Heuvel‐Eibrink MM. Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Haematologica. 2014;99(3):430‐436.
Kempf SJ, Moertl S, Sepe S, et al. Low‐dose ionizing radiation rapidly affects mitochondrial and synaptic signaling pathways in murine hippocampus and cortex. J Proteome Res. 2015;14(5):2055‐2064.
Nadeau G, Ouimet‐Grennan E, Aaron M, et al. Identification of genetic variants associated with skeletal muscle function deficit in childhood acute lymphoblastic leukemia survivors. Pharmgenomics Pers Med. 2019;12:33‐45.
Aaron M, Nadeau G, Ouimet‐Grennan E, et al. Identification of a single‐nucleotide polymorphism within CDH2 gene associated with bone morbidity in childhood acute lymphoblastic leukemia survivors. Pharmacogenomics. 2019;20(6):409‐420.
Rodier F, Coppé J‐P, Patil CK, et al. Persistent DNA damage signalling triggers senescence‐associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973‐979.
Bhaumik D, Scott GK, Schokrpur S, et al. MicroRNAs miR‐146a/b negatively modulate the senescence‐associated inflammatory mediators IL‐6 and IL‐8. Aging (Albany NY). 2009;1(4):402‐411.